deltatrials
Unknown PHASE1 INTERVENTIONAL 8-arm NCT03374007

Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma (GB226)

With Open, Single/Multiple Dosing and Dose Escalation, Phase I Clinical Trial Scheme to Evaluate Safety, Tolerance and Pharmacokinetic Properties of Genolimzumab Injection

Sponsor: Genor Biopharma Co., Ltd.

Conditions Advanced Solid Tumor Lymphoma Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma Recurrent Solid Tumor
Interventions Geptanolimab Injection 10mg/kg Geptanolimab Injection 10mg/kg, , q2w*6 Geptanolimab Injection 1mg/kg Geptanolimab Injection 1mg/kg, q2w*6 Geptanolimab Injection 280mg, q3w Geptanolimab Injection 3mg/kg Geptanolimab Injection 3mg/kg, q2w Geptanolimab Injection 3mg/kg, q2w*6
Updated 10 times since 2017 Last updated: Aug 12, 2021 Started: Oct 19, 2017 Primary completion: Jun 30, 2022 Completion: Aug 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Tumor and Lymphoma and is currently ongoing. Genor Biopharma Co., Ltd. leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotRecruiting~Jun 2018 – ~Dec 2019 · 18 months · monthly snapshotRecruiting~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshotRecruiting~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshotRecruiting~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshotRecruiting~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshotRecruiting~Sep 2021 – ~Apr 2023 · 19 months · monthly snapshotRecruiting~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1

    Status: Unknown Status → Unknown

  3. Apr 2023 — Jul 2024 [monthly]

    Unknown Status PHASE1

    Status: Recruiting → Unknown Status

  4. Sep 2021 — Apr 2023 [monthly]

    Recruiting PHASE1

  5. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

▶ Show 5 earlier versions

  1. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  2. Jan 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  3. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  4. Jun 2018 — Dec 2019 [monthly]

    Recruiting PHASE1

  5. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

    First recorded

Oct 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genor Biopharma Co., Ltd.
Data source: Genor Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations